Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27193524 | 0.83 | SSTR4 (0.41) | — | |
| SCHEMBL15409473 | 0.83 | SSTR4 (0.41) | — | |
| SCHEMBL27193447 | 0.83 | SSTR4 (0.41) | — | |
| SCHEMBL27193601 | 0.83 | SSTR4 (0.41) | — | |
| SCHEMBL15409471 | 0.83 | SSTR4 (0.41) | — | |
| Hydrochloric Acid SCHEMBL27193474 | 0.82 | SSTR4 (0.41) | — | |
| SCHEMBL2304542 | 0.79 | GBA1 (0.44) | — | |
| SCHEMBL2304538 | 0.79 | GBA1 (0.44) | — | |
| SCHEMBL2304547 | 0.79 | GBA1 (0.44) | — | |
| SCHEMBL27585740 | 0.77 | CTSD (0.37) | CTSDCHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414252-B1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022087624-A1 | COMPOUNDS AS RAS INHIBITORS AND USES THEREOF | BIOARDIS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3414252-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139778-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1945646-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome (UK) Ltd. (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | HRH4, HRH3, HRH2 | CTSD 2333/4885CHRNB2 2721/4885CHRNB4 1802/4885 |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | CTSD 434/4885CHRNB2 3612/4885CHRNB4 4083/4885 |
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | CTSD 4208/4885CHRNB2 4675/4885CHRNB4 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.